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Data regarding convenient, valid methods for measuring U.S.
isoflavone intake are limited. We evaluated a soy food questionnaire (SFQ), the Willett food frequency questionnaire (FFQ), and
overnight urine samples relative to excretion in 24-h urine samples.
We also described intake among women in a high-risk program for
breast or ovarian cancer. Between April 2002 and June 2003, 451
women aged 30 to 50 yr with a family history of breast or ovarian
cancer completed the SFQ and FFQ. Of them, 27 provided four
24-h and overnight urine specimens. In these women, 24-h sample
measures were correlated with SFQ estimates of daidzein (Spearman r = .48) and genistein (r = .54) intake, moderately correlated
with the Willett FFQ (daidzein r = .38, genistein r = .33), and
strongly correlated with overnight urine excretion (daidzein r =
.84, genistein r = 0.93). Among all 451 SFQ respondents, mean
(median) daidzein and genistein intakes were 2.8 (0.24) and 3.9
(0.30) mg/day. Primary sources of both were soymilk, soy nuts,
and tofu. We conclude that targeted soy food questionnaires, com-

prehensive FFQs, and multiple overnight urines are all reasonable
options for assessing isoflavone intake in epidemiologic studies.

INTRODUCTION
Ecologic (1), epidemiologic (2), and experimental (3) research has suggested that soy or isoflavone intake can reduce
risk of breast cancer, but whether current levels of isoflavone
intake in the usual U.S. diet are sufficiently high to affect breast
cancer risk remains unclear. The marketing of soy as a health
food and the greater popularity of nonmeat protein alternatives
have contributed to a substantial rise in the availability and purchase of soy-containing products (4–6). Although statistics on
isoflavone intake are not available, sales of soy-based products
increased 20% per year since 1995 compared with <10% before
1995 (7). The increase may be especially pronounced in healthconscious individuals, such as women with a family history of
breast cancer, who are likely more motivated to modify their
lifestyle to reduce their breast cancer risk (8).
A primary obstacle to describing intake and health effects of
isoflavones consumed in a population is the lack of a convenient

and validated method for measuring intake. Only two studies,
to our knowledge, have evaluated the relative validity of such
a dietary instrument against isoflavone excretion in multiple
24-h urine samples (9,10). Several studies have used spot or
overnight urine excretion as alternatives because of their ease
of implementation relative to 24-h samples, but one study that
compared overnight urine excretion to 24-h samples found only
moderate correlations between the two measures (9).
The objectives of this study were to evaluate the validity and
reproducibility of a soy food questionnaire (SFQ) developed for
non-Asian women; to evaluate two other methods—the Harvard
Diet Assessment Form (DAF) (11) and multiple overnight urine
samples—for their adequacy in ranking women relative to 24-h
urine samples; and to use the SFQ to describe levels of intake
and main food sources of isoflavones in a sample of women
enrolled in a program for women at potentially high genetic risk
for breast or ovarian cancer.
MATERIALS AND METHODS
Study Sample
Subjects in this study were drawn from the Family Risk
Assessment Program (FRAP) at the Fox Chase Cancer Center
(FCCC) in Philadelphia. FRAP was initiated in 1991 to offer
education and preventive interventions to women with at least
one first- or second-degree relative with breast or ovarian cancer.
Recruitment strategies include referrals from breast or ovarian
cancer patients at FCCC, radio and newspaper advertisements,
and physician and self-referrals. On enrollment, women complete a health history questionnaire that elicited information on
sociodemographic factors, reproductive factors, and family and
medical history.
Between April 2002 and June 2003, an SFQ and the 126-item
DAF (11) were sent to each of 893 FRAP subjects between the
ages of 30 and 50 yr; 3 women had passed away, and 7 women
were determined to be ineligible (due to having participated
in a related study), leaving 883 potential respondents. Of 883
potentially eligible respondents, 371 did not return packets, 44
could not be contacted by mail or telephone, and 17 indicated
that they were not interested in participating, leaving a sample
of 451 respondents. Of these, a subset of 27 women agreed
to provide urine specimens for comparison with questionnaire
estimates.
The protocol for this research was reviewed and approved by
the Fox Chase Cancer Center Institutional Review Board.
Assessment of Isoflavone Intake
We developed an SFQ and an accompanying database of
isoflavone content values to estimate frequency of intake of soycontaining foods and level of intake of daidzein and genistein.
A detailed description of the SFQ has been provided previously
(12). Briefly, the SFQ followed the format of the DAF. The list
of items in the SFQ and its accompanying database of isoflavone

values were developed from tables and databases representing
all currently available information on the isoflavone content of
over 100 food items (13–18). These data were supplemented
with information obtained from soy food manufacturers and
with detailed soy intake information from pilot testing in 12
women who completed a draft version of the soy food questionnaire and were then interviewed for qualitative feedback on
the questionnaire and on their soy food eating habits in general.
Their responses led to deletion of infrequently eaten items from
the food list (e.g., soy pizza) and to refinement of foods included
as the basis for the isoflavone database.
For each food item, subjects indicated the average frequency
that they consumed a specified portion size of the food over
the past year, with 9 frequency options ranging from “never,
or less than once per month” to “6+ per day.” For soy protein bars and powders, we estimated mean frequency of intake
based on the respondent’s frequency of consumption of any
protein bars/powders and how often the protein bars/powders
were soy protein based. We then estimated frequency of intake
soy protein bars/powders as 0, 0.33, 0.67, or 1.0 times the frequency of all protein bars/powders if women reported that the
protein bars/powders they consumed were, respectively, “never
or almost never,” “sometimes,” “often,” or “always or almost
always” soy protein based. When women reported that they did
not know, we assumed that the product did not contain soy. The
questionnaire also included an open-ended section asking about
intake of soy supplements and of other soy-based foods eaten
at least once a month. To estimate daidzein and genistein intake
from the SFQ, intake of specific isoflavones was estimated by
multiplying frequency of intake of each food by the isoflavone
content for the food’s portion size.
We also estimated daidzein and genistein intake based on
responses to the DAF using a previously described method (19).
In this method, isoflavone values were assigned to each food
item in the DAF using values identified in the literature and
unpublished data from experts in the field. The phytoestrogen
content of each food item was assigned a score (0, 0.0005,
0.005, 0.05, 0.5, 5, or 50 mg/100 g wet weight of food) to
avoid implying a degree of accuracy for which current data
on isoflavone content are too limited. The score for each food
item was then multiplied by the serving size and frequency
of consumption of the food and then summed across foods to
estimate total intake.

Assessment of Urinary Phytoestrogens
From 27 women who agreed to provide urine samples, four
24-h urine specimens were collected for four 24-h periods, each
beginning with the sample following the first void of the selected
day, over the period of 1 mo. Two samples were requested during
each half of each woman’s menstrual cycle. Subjects received
4-l containers with 4 g of ascorbic acid to prevent microbial
contamination and oxidative degradation. They were asked to
use a separate container for the overnight urine sample, or the

first void of the next day, and to store the overnight and restof-day sample containers in their refrigerators until pick-up the
next morning.
On transport to the FCCC, total 24-h urine volume was
recorded, and sodium azide was added to achieve a 0.1%
(wt/vol) concentration. After extracting separate 25-ml aliquots
of overnight samples, remaining overnight samples were combined with rest-of-day samples in correct proportions to create
pooled 24-h samples, which were also put into 25-ml aliquots.
All samples were stored at –20◦ C until shipment to the laboratory of Dr. Mindy Kurzer at the University of Minnesota for
phytoestrogen analyses or to Quest Diagnostics for analysis of
urinary creatinine using a kinetic colorimetric assay [interassay
coefficients of variation (CV) of 2–3%].
Procedures for analyzing urinary specimens for phytoestrogens have been described (20). Briefly, immediately before analysis, urine aliquots were thawed. Each of the 4 overnight samples were combined to create a pooled overnight urine sample.
The four 24-h urine aliquots were similarly pooled. Fifteen-ml
aliquots from each pooled overnight, and 24-hour urine samples
were extracted.
Samples were analyzed for phytoestrogens, including the
3 major soy isoflavones (daidzein, genistein, glycitein) and 2
metabolites of daidzein [O-desmethylangolensin (ODMA) and
equol], using an ion-exchange chromatography and capillary
gas chromatography-mass spectrometry method (21) in which
phytoestrogens were first extracted on Bond Elut C18 columns.
Deuterated phytoestrogen and estrogen internal standards were
added to each sample. The aliquots were then hydrolyzed with
Helix pomatia enzyme extract. The isoflavonoid fraction was
separated from the rest of the compounds on the acetate form
of QAE-Sephadex columns. Trimethylsilyl derivatives of the
samples and standards were analyzed by a Hewlett Packard 5890
and 5971A quadrupole gas chromatography-mass spectrometry
instrument operated with a Unix 59940A ChemStation and a
HP 7673 autosampler (Agilent Technologies, Santa Clara, CA)
in the selective ion-monitoring mode. Intraassay CVs ranged
from 4.0–10.8%, and interassay CVs ranged from 9.7–23.5%
for analyses of the 5 phytoestrogens examined here. All samples
from each subject were analyzed in duplicate in the same batch.

Statistical Analyses
We used Spearman correlations to compare isoflavone estimates from the SFQ, estimates from the DAF, and urinary
isoflavone excretion in overnight urine samples with 24-h urine
samples (in nmol/mg creatinine).
In addition to estimating total daily daidzein and genistein
intake for each respondent, we calculated total daidzein and
genistein intake over the entire sample as the sum of daidzein
and genistein intake over all respondents. This sum was then
used to calculate the contribution of each individual soy food
from the SFQ to total daidzein or genistein intake—specifically,
by calculating the amount from the particular food summed

over all respondents then dividing by total intake for the entire
sample.
All analyses were conducted using Statistical Analysis Software (SAS) release 9.1 (SAS Institute Inc., Cary, NC).

RESULTS
Characteristics of the sample that responded to the SFQ
(N = 451) and of the subset that provided urine specimens
(N = 27) are shown in Table 1. Mean (SD) age of the full sample of respondents (N = 451) was 41.9 yr (5.3), most (96%)
women were White, and most (66%) had attained at least a
college degree. The subsample (N = 27) was similar to the full
sample with respect to sociodemographic characteristics as well
as intake of energy, fat, and fiber. The SFQ and DAF gave different pictures of daidzein and genistein intake in the full and
subsamples, however. Whereas the SFQ estimated higher median intake of the two isoflavones in the full sample compared
with the subsample, the DAF showed similar estimates of median intake between the two samples. With respect to urinary
measures, daidzein was the most abundant isoflavone detected
in both 24-h and overnight samples, followed by genistein.
Daidzein and genistein intake estimated from the SFQ
was correlated with their excretion in 24-h urine specimens
(Table 2). The correlation for daidzein was similar when
daidzein metabolites (ODMA and equol) were included (Spearman r = .49). To exclude the influence of extreme observations
on our correlations, we excluded four subjects with 0 isoflavone
intake based on the SFQ and 1 subject with isoflavone intake
>100 mg/day. Excluding these subjects substantially increased
Spearman correlations for both daidzein (r = .63) and genistein
(r = .63). In an examination of individual items in the SFQ, the
three that were most highly correlated with daidzein excretion
were soymilk (r = .51), vegetable burgers (r = .50), and soy
nuts (r = .33), whereas the three most highly correlated with
genistein excretion were soymilk (r = .50), vegetable burgers
(r = .48), and tofu (r = .38). Correlations for estimates based
only on two items, soymilk and vegetable burgers, were .61 for
daidzein and .60 for genistein. Excluding the four subjects with
0 isoflavone intake and the one subject with isoflavone intake
>100 mg/day did not change the correlations nor did adding
in estimates from other individual food items meaningfully improve these correlations (results not shown).
Correlations for daidzein and genistein intake estimated from
the DAF were weaker but still moderate when compared with
24-h urine sample measures (Table 2). When daidzein metabolites were also included, the correlation for daidzein improved
considerably (r = .54). Isoflavones measured in overnight urines
were strongly correlated with their corresponding measures in
24-h samples (Table 2). The correlation between overnight and
24-h samples for all 5 isoflavones summed together was .91.
We estimated isoflavone intake among the full sample of
respondents to the questionnaire (N = 451). Mean (SD) daily
intakes of daidzein and genistein estimated from the SFQ were

TABLE 1
Characteristics of All Respondents to Soy Food Questionnaire and Subset of Participants Providing Urine Specimensa
Main Study Sample (N = 451)
Mean (SD) age (yr)
White (%)
Highest grade completed (%)b
<College degree
College degree
>College degree
Mean (SD) BMI (kg/m2 )
Mean (SD) daily intake
Energy (kcal)
Energy from fat (%)
Fiber (mg)

Isoflavone Intake (mg/day)
Daidzein
SFQ
DAF
Genistein
SFQ
DAF
Urinary excretion (ng/mg creatinine)
24-h urine
Daidzein
Genistein
Glycitein
ODMA
Equol
Overnight urine
Daidzein
Genistein
Glycitein
ODMA
Equol

Subsample (N = 27)

41.9 (5.3)
96

41.3 (4.5)
96

33
40
27

22
56
22
25.4 (6.5)

—
7,622 (2805)
32 (7)
19 (10)

7,803 (2562)
32 (5)
19 (8)

Main Study Sample

Subsample

Mean (SD)

Median
(Interquartile Range)

Mean (SD)

Median
(Interquartile Range)

2.8 (7.4)
2.3 (8.7)

0.237 (0–1.485)
0.029 (0.020–0.058)

2.9 (9.4)
2.1 (4.6)

0.015 (0.007–1.310)
0.032 (0.023–3.331)

3.9 (10.4)
2.4 (8.8)

0.302 (0–1.972)
0.097 (0.050–0.325)

3.9 (12.2)
2.2 (4.6)

0.013 (0.006–2.000)
0.129 (0.053–3.438)

—
—
—
—
—

—
—
—
—
—

313.4 (618.9)
136.4 (161.2)
42.6 (84.2)
88.9 (208.5)
122.9 (425.2)

110.3 (52.2–428.4)
67.4 (25.6–201.4)
16.2 (3.6–39.9)
18.9 (6.5–44.5)
12.8 (2.3–29.1)

—
—
—
—
—

—
—
—
—
—

419.7 (885.6)
250.5 (476.3)
58.1 (139.3)
93.4 (232.0)
84.3 (274.1)

135.0 (87.8–397.4)
77.2 (33.5–264.5)
11.1 (3.3–44.6)
15.5 (8.7–70.6)
10.0 (7.2–20.9)

All respondents to soy food questionnaire, N = 451; participants providing urine specimens, N = 27. Abbreviations are as follows: BMI,
body mass index; SFQ, soy food questionnaire; DAF, Harvard Diet Assessment Form; ODMA, O-desmethylangolensin.
b
Due to missing data, education level is described for N = 446 in the full study sample.
a

2.8 (7.4; median = 0.24) and 3.9 (10.4; median = 0.30) mg/day,
respectively, higher than estimates based on the DAF (for
daidzein, mean = 2.3, SD = 8.7, median 0.03; for genistein,
mean = 2.4, SD = 8.8, median 0.10). The 10 top sources of the
two isoflavones (genistein + daidzein) based on the SFQ are
shown in Table 3. Together, these sources accounted for 87%
of total daidzein and genistein intake in our sample. Although
soymilk was the most important contributor to total isoflavone
intake in the sample, more women (30%) consumed vegetable
burgers than any other soy food or soy-containing food. Among

women reporting consumption of any given food, soy milk and
soy cereal were the most frequently consumed.

DISCUSSION
Our findings extend the field of isoflavone intake assessment
in several ways. First, we found that our 26-item SFQ performed well in ranking women according to their daidzein and
genistein intake compared with multiple 24-h urine specimens,
although correlations were even higher for estimates based on

TABLE 2
Spearman Correlations With Isoflavone Levels (ng/mg
Creatinine) in Multiple 24-h Urine Samplesa
SFQ

DAF

Multiple Overnight
Urine Samples

.48
.54
—
—
—

.38
.33
—
—
—

.84
.93
.76
.84
.61

Daidzein
Genistein
Glycitein
ODMA
Equol

a
N = 27. Abbreviations are as follows: SFQ, soy food
questionnaire; DAF, Harvard Diet Assessment Form; ODMA,
O-desmethylangolensin.

only 2 of the 26 items (soymilk and vegetable burgers). Thus,
our work offers ideas for assessing isoflavone intake using a
potentially reducible soy questionnaire module appropriate for
a non-Asian, Eastern U.S. population. Second, our analysis is
among the first to demonstrate that a comprehensive FFQ yields
reasonable correlations with excretion in 24-h urine samples.
Our analysis is also among the first to demonstrate that multiple overnight urine samples are strongly correlated with 24-h
urine samples—clearly more strongly correlated than were any
TABLE 3
Ten Top Sources of Dietary Daidzein and Genistein Among
Respondents to the SFQa
Mean
Total
Monthly
genistein + Respondents Frequency of
Daidzein
Consuming Consumption
Intake in
at Least
Among
Sample
Once per
Consumers
Month (%)
of the Food
(%)b
Soy milk
Soy nuts
Tofu
Soy bars
Soy powders
Vegetable burgers
Green soybeans
Soy yogurt
Soybeans
Soy cereal
Total

27.5
16.7
10.4
10.1
8.2
4.3
2.8
2.6
2.2
2.0
86.7

14
13
17
10
6
30
12
2
4
3

16
8
5
7
9
4
3
8
2
12

N = 451. Abbreviation is as follows: SFQ, soy food questionnaire.
Calculated as amount of daidzein + genistein from the individual food summed over all respondents divided by total daidzein and
genistein intake over entire sample.
a
b

of the questionnaire-based estimates. Many studies have used
overnight urines as a referent to evaluate questionnaire-based
isoflavone estimates, but only one study, to our knowledge,
evaluated overnight urine samples by comparing them against
a more rigorous referent, multiple 24-h urine samples, and that
study showed substantially more modest correlations than did
our data (9). Finally, our study is the first to describe isoflavone
intake in a sample of women at potentially high genetic risk for
breast or ovarian cancer. In this sample, we found generally low
levels of isoflavone intake. Top contributors to total isoflavone
intake were soymilk, soy nuts, and tofu, but vegetable burgers
were consumed by more women in our sample than any other
soy food.
Our SFQ compares favorably with other such questionnaires
developed for non-Asian samples. Correlations between questionnaire estimates and either urine (22) or plasma (23,24) samples were .3 for a 6-item module (22), .4 for a 20-item module
(23), and .5 for a 40-item module (24), all developed for samples in Washington state. The correlation with an overnight
urine sample for an isoflavone intake estimate based on 12 soycontaining foods was .3 for annual and .6 for recent soy intake
in a multiethnic sample in Hawaii (25); but in a subsequent analysis, the tetrachoric correlation for the same questionnaire was
.88 including both control and intervention subjects in a soy intervention study (26). Estimates based on 6 to 8 soy-containing
items within a FFQ were moderately correlated (r = .2–.4) with
either urine or serum measures in studies conducted in Japan
(27) and China (28,29).
We found a correlation of r = .6 when we based isoflavone
estimates on only two items (soymilk and vegetable burgers)
compared with a correlation of ≈.5 based on all the soy foods
in the questionnaire. Because we would expect that including
more soy foods would improve estimates and correlations, this
finding indicates substantial error in estimating isoflavone intake from other soy food items. The source of error is not clear
and could include inaccurate recall of dietary intake, inaccurate
isoflavone content values, or differences in the bioavailability
of isoflavones from different food sources (30). Lampe et al.
(10) observed correlations of only ≈.2 between daidzein and
genistein excretion in multiple 24-h urine samples and soy intake estimated from a single FFQ item (tofu or soybeans). Other
researchers, however, have found that 2 to 3 soy food items
are sufficient to rank individuals based on their isoflavone intake. Verkasalo et al. (31) found a strong correlation (r = .7)
with plasma concentrations for daidzein and genistein estimates
based on two items (tofu, soy foods) in a sample of women
that was selected to represent a wide range of soy food intake.
In work by Frankenfeld et al. (23,24), correlations with plasma
measures for daidzein and genistein estimates based on two
items (tofu and soymilk) were only slightly lower than those
observed for 20- and 40-item SFQs. Similarly, Yamamoto et al.
(27) found that 3 soy food items were sufficient to yield correlations with a 24-h urine measure that were comparable to those
based on the original 8 items.

Together, these findings suggest that a small number of soycontaining items is sufficient to explain variability in isoflavone
intake and that an extensive module to assess soy food intake is
probably not necessary. Nevertheless, selecting the appropriate
items for a given population requires continued monitoring of
soy food trends, especially given rapid changes in eating habits,
soy product availability, and isoflavone content. In the United
States, for example, whereas soymilk and tofu have remained
relatively constant sources of isoflavones in the American diet
since the mid-1990s (15,24,32), sales of tofu have recently leveled, and soy snacks are emerging as a popular, new category of
soy foods (33,34). Indeed, soy nuts, although they have not been
reported as a significant food item in earlier work (15,24,32),
were a primary isoflavone source in our sample, and many subjects also reported consumption of soy chips (data not shown).
Selecting the soy food items to include in a module may also
require consideration of some statistical issues. In our sample,
for example, vegetable burgers were the second most highly
correlated but contributed only 4.3% to total isoflavone intake,
suggesting that it was able to capture intraindividual variability
in isoflavone intake despite its relatively moderate contribution
to total isoflavone intake.
The correlations that we observed for the DAF were comparable to those obtained in previous work using other comprehensive FFQs. This was despite the use of an alternative method of
assigning phytoestrogen values to FFQ food items that assigned
categories instead of exact phytoestrogen content values (19).
In a study including 51 Japanese American women, the correlations for daidzein and genistein intake estimated from a modified
Block FFQ were .49 and .30, respectively, using multiple, 24-h
urine samples as the referent (9). In another study of 58 South
Asian women, correlations for intake estimated from a 207-item
FFQ were .32 and .21 for daidzein and genistein, respectively,
with multiple plasma samples as the referent (35). These findings suggest that a comprehensive FFQ can provide a reasonable ranking of individuals based on their isoflavone intake even
when the FFQ does not specifically target soy foods, indicating
the importance of nonsoy sources of isoflavones (19,32). Among
postmenopausal women in the Framingham Offspring Study, for
example, soy (tofu and soybeans) contributed only 3.3% to total
isoflavone intake, whereas beans and peas, tea, coffee, and nuts
were the main contributors, together accounting for >55% of
total intake (19). How well an open-ended section in such FFQs
can improve correlations is unclear. Ideally, at least one or two
soy food items should be added to improve estimates.
Only 2 other studies, to our knowledge, have compared FFQ
estimates of isoflavone intake against excretion in multiple,
24-h urine specimens (9,10). Others have used measures in a
single, 24-h sample (27), in overnight or spot urine samples
(22,25,28), or in serum or plasma (23,24,31,35). How well such
measures reflect intake is unclear given that daidzein and genistein have a half-life of ≈8 h and are mostly excreted within
12 h of ingestion (36). In our sample, isoflavone measures in
overnight urine measures were generally very highly correlated

with 24-h urine measures—more strongly correlated than our
questionnaire-based estimates and also more strongly correlated
than was reported in previous work (9). Although our study procedures did not permit an assessment of the adequacy of 1 vs.
multiple overnight urines, a previous study found no significant difference in isoflavone excretion comparing 2 separate
overnight samples in a sample of women in Washington State
(22). In another study, the analysis of first morning urine collected once, combined from 3 days a week and combined from
3 days a week over 1 mo, all showed excellent correlations,
indicating that urine from a single overnight collection is as
good as one collected over 3 days per week or over 1 entire
mo (37). Thus, for ranking of isoflavone intake and excretion,
overnight urine samples represent a good alternative to 24-h
urine samples. Collection of 24-h urine samples poses a burden
to study subjects as well as study organizers and can result in
bias because of the high potential for both nonparticipation and
noncompliance among subjects. In general, when working with
a large, population-based sample, using the SFQ or a similar
questionnaire may be more feasible than obtaining urine-based
assessments of soy intake. However, when obtaining overnight
samples is feasible, or when working with a low-literacy population, overnight urines may be the preferable method.
Our results provide the first description, to our knowledge,
of isoflavone intake in women at potentially high genetic risk
for breast or ovarian cancer. When we used the SFQ to describe intake in this sample, we found estimates of intake that
were generally lower than those for samples in California (15),
Washington (23,24), and Hawaii (25). Possibly, these women
have controlled their soy intake as a result of concerns about the
estrogenic effects of isoflavones. In a previous analysis, however, only 7% of nonconsumers wrote that they avoided soy
foods for this reason (12). In our previous analysis, we found
that not knowing how to prepare soy foods and disliking the
taste of soy foods were the primary reasons for their nonconsumption (12). These reasons are the most likely explanations
for our subjects’ generally low level of isoflavone intake and for
their more frequent consumption of vegetable burgers in favor
of richer but less familiar isoflavone sources such as tofu.
The scope of our work directly addressed only the validity of questionnaires and overnight urine samples for assessing isoflavone intake in epidemiologic studies. Budgetary constraints necessitated the pooling of the four 24-h and overnight
urine samples for laboratory analyses, thus limiting our ability
to evaluate interindividual variability in the isoflavone content
of urine samples or the validity of analyzing single, overnight
urine samples as a more convenient measure of isoflavone intake. Evaluating measures to estimate absolute level of intake in
individuals as opposed to relative intake within a population was
also beyond the scope of our analysis. These merit investigation
in future studies.
Findings are subject to bias if subjects were systematically
different from nonsubjects. In a previous analysis (12) we
found that respondents to the SFQ were slightly older than

nonrespondents (mean age = 42 vs. 41 yr) and more likely to
be college educated (66% vs. 57%), but they were similar with
respect to other demographic characteristics and health behaviors. We observed no significant differences in demographic
characteristics or health behaviors, including isoflavone intake,
between SFQ respondents (N = 451) and subsample subjects
(N = 27).
Also worth noting is that our sample consisted of subjects in
a program for women with a family history of breast or ovarian
cancer; thus, our estimates of soy and isoflavone intake apply
to more health-conscious, potentially high-risk populations. We
have no reason to expect, however, that the correlations we observed between questionnaire-based estimates and isoflavones
excreted in the urine would differ from average-risk women.
Thus, we believe that our conclusions regarding measurement
of soy and isoflavone intake are applicable to a broader population.
In conclusion, we found that a 26-item SFQ performed well
in ranking women based on their daidzein and genistein intake.
As few as two items, however, perform as well or better, but
selection of the items requires consideration of trends in soy
food availability and consumption and validation in an appropriate sample. We also found that a comprehensive FFQ not
specifically designed to assess isoflavone intake also performed
reasonably well and that multiple overnight urines were strongly
correlated with 24-h urine measures. Our work provides several
options for assessing isoflavone intake in epidemiologic studies.
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